EpiSign Launches METRIC 5-base for Enhanced DNA Methylation Analysis
EpiSign Inc. has launched EpiSign METRIC 5-base, a comprehensive tool aimed at extending episignature analysis capabilities from methylation microarrays to DNA sequences derived from advanced sequencing technologies. This new software facilitates the analysis of methylation data generated via Illumina 5-base, PacBio HiFi, and Oxford Nanopore sequencing, all through a unified classification framework established in EpiSign METRIC Version 6. By automating the analysis of over 300 episignature disorders, the software is intended to simplify complex genetic analyses for laboratories globally affiliated with the EpiSign Clinical Testing Network.
Recent advancements in genome-sequencing technologies have enabled labs to capture detailed genetic and epigenetic information within the same dataset. However, a significant challenge remains in translating these sequencing-derived methylation signals into standardized interpretations, particularly for rare diseases. EpiSign METRIC 5-base addresses this challenge by providing a ready-to-use analytical framework, eliminating the need for laboratories to create and maintain numerous disease-specific classifiers and analytical pipelines independently.
The workflows of EpiSign METRIC 5-base underwent thorough technical validation across the three supported sequencing platforms and exhibited performance benchmarks comparable to the previously established EpiSign METRIC for methylation arrays. Following this initial validation, broader site-level evaluations will occur using locally sourced sequencing data through the Clinical Testing Network.
Dr. Bekim Sadikovic, EpiSign's Chief Scientific Officer, stated that the METRIC 5-base launch represents a significant leap by allowing labs using various technologies—microarrays and different sequencing methods—to benefit from a unified classification system. This integration encourages a more comprehensive approach to analyzing both genetic and epigenetic data.
Dan Sinai, EpiSign's CEO, emphasized the company’s goal to facilitate sophisticated epigenomic interpretations without necessitating each laboratory to construct unique analytical infrastructures. The EpiSign METRIC 5-base platform presents laboratories with a straightforward method to adopt sequencing-based episignature analysis through established networks.
Prominent clinical diagnostic laboratories are already engaging with this new offering. For instance, Ambry Genetics conducted an initial evaluation using PacBio HiFi sequencing data, noting the potential of EpiSign METRIC to enhance the understanding of uncertain genomic findings. Additionally, Amsterdam UMC and Greenwood Genetic Center are participating as early-access sites, leveraging their local sequencing capabilities to further validate this tool.
Dr. Marielle van Gijn from Amsterdam UMC highlighted the advantages of Oxford Nanopore sequencing, which allows long-read genomic insights and native DNA methylation data integration. The initial results from ONT-derived methylation data suggest a promising performance, with ongoing clinical validations.
Greenwood Genetic Center, recognized for integrating long-read genomic sequencing in clinical practice, sees the value in incorporating DNA methylation analysis into its operations to enhance diagnostic capabilities. Dr. Matthew Tedder from Greenwood expressed optimism about evaluating EpiSign METRIC 5-base within their existing workflows.
The official launch date for EpiSign METRIC 5-base is September 30, 2026, with research access available for laboratories interested in early validation or participation in the Clinical Testing Network.
EpiSign Inc. specializes in advanced DNA methylation analysis software tailored for rare disease and clinical applications, thus contributing significantly to the evolving landscape of genomic analysis. For more information or access requests, laboratories can reach out to EpiSign.
We use essential cookies to make this site work. With your permission, we'd also like to use analytics cookies to understand how people use the site, and marketing cookies to measure our outreach. You can change your choice any time. Privacy policy
Choose which cookies you allow. Essential cookies are always on because the site can't work without them.
Keep the site secure, remember your cookie choice and make core features work.
Help us understand which pages are visited and how people find us (Google Analytics). Data is aggregated.
Measure our campaigns and show relevant content on other platforms (e.g. Google Ads, LinkedIn, Meta).